Pancreatic Islets in Forefront of Diabete...( Cells could play major role in treat...),Health

Cells could play major role in treatment, if supply is adequate, study finds

TUESDAY, April 14 (HealthDay News) -- Pancreatic islets, which are hormone-producing cells, are becoming more prominent in diabetes research and could play a major role in future treatments, according to U.S. experts.

"The primary objective of islet-based research is to cure diabetes," John S. Kaddis, of the City of Hope National Medical Center, in Duarte, Calif., and his colleagues wrote in the April 15 issue of the Journal of the American Medical Association, a themed issue on diabetes.

"Perhaps the most prominent clinical application of this research is currently in the form of cell replacement therapy," they noted. "With the exception of one report in a type 2 diabetes cohort, islet transplantation has been used exclusively for a subset of individuals with type 1 diabetes mellitus and was shown, at least temporarily, to improve glucose control and, in a few cases, to lead to insulin independence."

Cell replacement therapy involves the transplantation of pancreatic islets from a donated pancreas to a person with diabetes. The goal is to restore the function of beta cells in the pancreas. The destruction of these cells causes type 1 diabetes.

"Although islet transplantation has been shown to offer both protection against long-term complications of the disease and significant improvement in quality of life, several obstacles remain, such as limited engraftment [acceptance of the islets within the recipient], chronic immunosuppression and inconsistent supply of human islets," the researchers noted. "These issues must be addressed if the procedure is to be used as a standard of care for qualified individuals."

To meet the increasing demand for human islets for transplantation and research, islet-sharing networks have been established. Between September 2001 and August 2008, 297.6 million islets were produced
'/>"/>